Facial recognition used to identify Lafayette Square protester accused of assault
By Justin Jouvenal, Spencer Hsu,
The Washington Post
| 11. 22. 2020
A line of U.S. Park Police officers pushed protesters back from Lafayette Square on June 1, firing pepper balls and rolling canisters spewing irritant gas into the retreating crowds on H Street NW, video shows.
Amid screams and smoke, a man in a tie-dye T-shirt pulled an officer to the ground and punched him in the face, before disappearing into the chaos, according to charging documents.
The man grabbed another officer, before police caught up with him and attempted to make an arrest, authorities said. But the man wrestled free and vanished once again.
The protester might never have been identified, but an officer found an image of the man on Twitter and investigators fed it into a facial recognition system, court documents state. They found a match and made an arrest.
The court documents are believed to be the first public acknowledgment that authorities used the controversial technology in connection with the widely criticized sweep of largely peaceful protesters ahead of a photo op by President Trump. The case is one of a growing number nationwide in which...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
